🇺🇸 FDA
Patent

US 11382897

Therapeutic combination for treatment of cerebellar ataxia

granted A61KA61K31/197A61K31/423

Quick answer

US patent 11382897 (Therapeutic combination for treatment of cerebellar ataxia) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/197, A61K31/423, A61P, A61P21/00